Regulatory Guidance And Enabling Compliance
-
How The FDA's 2024 Draft Guidances Will Influence CGT Regulation In 2025
4/8/2025
Kimberly Benton, Ph.D., Master Principal and Head of Regulatory at Dark Horse Consulting and Bambi Grilley, RPh, RAC, CIP, CCRC, CCRP, Director, Clinical Research and Early Product Development Center for Cell and Gene Therapy, Professor of Pediatrics Baylor College of Medicine, and Chief Regulatory Officer of International Society for Cell & Gene Therapy (ISCT) share why the FDA’s 2024 draft guidance documents are expected to shape regulatory standards for cell and gene therapy in 2025, with topics ranging from safety testing of allogeneic cells to manufacturing practices and the use of human and animal-derived materials.
-
CAR-T Innovation: Balancing Allogeneic And Autologous Cell Therapy
6/30/2025
Join experts as they discuss strategies for optimizing allogeneic and autologous therapies, aiming for balanced development and wider patient accessibility by 2030.
-
Microbial Identification Via DNA-Seq
6/9/2025
Learn how DNA sequencing-based microbial identification supports regulatory compliance and enhances contamination control in critical environments.
-
Successful Microbial Testing And Identification
5/27/2025
In this presentation, one of our industry-leading customers discusses how they've successfully implemented the Applied Biosystems MicroSEQ Microbial Identification System in their laboratory testing.